Novartis’ Outcome Program May Prove Galvus A GLORIOUS First-Line Therapy
Executive Summary
Novartis hopes to establish Galvus as a treatment for use in early stage type 2 diabetes through a program of outcomes trials for the dipeptidyl peptidase IV inhibitor
You may also be interested in...
Novartis Takes Aim: Galvus Promotions To Target Other Classes, Not Januvia
Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia
Novartis Takes Aim: Galvus Promotions To Target Other Classes, Not Januvia
Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia
Outcomes Studies Are Key To Validating Metabolic Syndrome As A Disease
European regulators have indicated that providing data from outcomes trials would be the best way to validate metabolic syndrome as a treatable condition, according to RenaSci Consultancy Director David Heal